DGI:Lymeborreliose/Quellen: Difference between revisions
imported>Brinkery (Die Seite wurde neu angelegt: „Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. ''Infect Dis Clin North Am''. 2015;29(2):269-280. doi:10.1016/j.idc.2015.02.004 Steere AC, A…“) |
imported>Brinkery No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Quellen== | |||
Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. ''Arthritis Rheum''. 2006;54(10):3079-3086. doi:10.1002/art.22131 | *Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. ''Infect Dis Clin North Am''. 2015;29(2):269-280. doi:10.1016/j.idc.2015.02.004 | ||
*Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. ''Arthritis Rheum''. 2006;54(10):3079-3086. doi:10.1002/art.22131 | |||
*Grillon A, Scherlinger M, Boyer PH, et al. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. ''Semin Arthritis Rheum''. 2019;48(6):1105-1112. doi:10.1016/j.semarthrit.2018.09.007 | |||
*<span class="ve-pasteProtect" style="box-sizing: inherit; font-family: Arial, sans-serif;" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}">Hofmann H, et al. ''S2k-Leitlinie Kutane Lyme Borreliose'', 2016</span> | |||
*<span class="ve-pasteProtect" style="box-sizing: inherit; font-family: Arial, sans-serif;" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}">Rauer S, Kastenbauer S. ''S3-Leitlinie Neuroborreliose'', 2018</span> | |||
*Kullberg BJ, et al., ''Lyme borreliosis: diagnosis and treatment.'' <span class="ve-pasteProtect" style="box-sizing: inherit; font-family: Arial, sans-serif;" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}">BMJ, 2020. 369:m1041. <span class="ve-pasteProtect" style="color: black" data-ve-attributes="{"style":"color: black"}">doi: 10.1136/bmj.m1041.</span> <span class="ve-pasteProtect" style="box-sizing: inherit;" data-ve-attributes="{"style":"box-sizing: inherit;"}"> </span></span> | |||
*<span class="ve-pasteProtect" style="box-sizing: inherit; font-family: Arial, sans-serif;" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}">Gaubitz M, et al., ''Empfehlungen der DGRh zur Therapie der Lyme-Borreliose, speziell des Erythema migrans sowie der Lyme-''</span> | |||
*NICE guideline 2018: ''Lyme disease'' | |||
*Goodlet KJ, Fairman KA. ''Adverse Events Associated With Antibiotics and Intravenous Therapies for Post–Lyme Disease Syndrome in a Commercially Insured Sample.'' <span class="ve-pasteProtect" style="box-sizing: inherit; font-family: Arial, sans-serif;" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}">Clin Infect Dis, 2018; 67(10):1568-1574</span> | |||
* <span class="docsum-authors" style="box-sizing: inherit;"><span style="box-sizing: inherit;">Cook MJ.</span></span> [https://pubmed.ncbi.nlm.nih.gov/25565881/ <span style="box-sizing: inherit;">Lyme</span> <span style="box-sizing: inherit;">borreliosis</span>: a review of data on transmission time after tick attachment.] <span style="box-sizing: inherit;"> </span><span class="docsum-journal-citation" style="box-sizing: inherit;">Int J Gen Med. 2014 Dec 19;8:1-8</span> | |||
* <span style="box-sizing: inherit; font-family: Arial, sans-serif;">Rahlenbeck S, Fingerle V „Ixodes ricinus Wie man sich vor Zecken schützt“ Deutsches Ärzteblatt Jg. 111 Heft 25 A 1142- A 1143</span> | |||
* <span style="box-sizing: inherit; font-family: Arial, sans-serif;">AWMF Leitlinie der Deutschen Dermatologischen Gesellschaft AWMF-Register-Nr. 013/044 Klasse: S2k „Kutane Lyme Borreliose“ https://www.awmf.org/uploads/tx_szleitlinien/013-044l_S2k_Kutane_Lyme_Borreliose_2016-05.pdf (letzter Zugriff: )</span> | |||
* Nau R, Christen HJ, Eiffert H „Lyme Disease – Current State of Knowledge“ Dtsch Ärztebl Int 2009; 106(5): 72-82 (Diskussion: https://www.aerzteblatt.de/pdf.asp?id=65524)<br /> | |||
Latest revision as of 13:37, 10 December 2020
Quellen
- Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. Infect Dis Clin North Am. 2015;29(2):269-280. doi:10.1016/j.idc.2015.02.004
- Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum. 2006;54(10):3079-3086. doi:10.1002/art.22131
- Grillon A, Scherlinger M, Boyer PH, et al. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. Semin Arthritis Rheum. 2019;48(6):1105-1112. doi:10.1016/j.semarthrit.2018.09.007
- Hofmann H, et al. S2k-Leitlinie Kutane Lyme Borreliose, 2016
- Rauer S, Kastenbauer S. S3-Leitlinie Neuroborreliose, 2018
- Kullberg BJ, et al., Lyme borreliosis: diagnosis and treatment. BMJ, 2020. 369:m1041. doi: 10.1136/bmj.m1041.
- Gaubitz M, et al., Empfehlungen der DGRh zur Therapie der Lyme-Borreliose, speziell des Erythema migrans sowie der Lyme-
- NICE guideline 2018: Lyme disease
- Goodlet KJ, Fairman KA. Adverse Events Associated With Antibiotics and Intravenous Therapies for Post–Lyme Disease Syndrome in a Commercially Insured Sample. Clin Infect Dis, 2018; 67(10):1568-1574
- Lyme borreliosis: a review of data on transmission time after tick attachment. Int J Gen Med. 2014 Dec 19;8:1-8
- Rahlenbeck S, Fingerle V „Ixodes ricinus Wie man sich vor Zecken schützt“ Deutsches Ärzteblatt Jg. 111 Heft 25 A 1142- A 1143
- AWMF Leitlinie der Deutschen Dermatologischen Gesellschaft AWMF-Register-Nr. 013/044 Klasse: S2k „Kutane Lyme Borreliose“ https://www.awmf.org/uploads/tx_szleitlinien/013-044l_S2k_Kutane_Lyme_Borreliose_2016-05.pdf (letzter Zugriff: )
- Nau R, Christen HJ, Eiffert H „Lyme Disease – Current State of Knowledge“ Dtsch Ärztebl Int 2009; 106(5): 72-82 (Diskussion: https://www.aerzteblatt.de/pdf.asp?id=65524)